Jason Aryeh Buys 202 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh bought 202 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was purchased at an average price of $112.51 per share, for a total transaction of $22,727.02. Following the acquisition, the director now owns 59,118 shares of the company’s stock, valued at $6,651,366.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

LGND traded down $0.20 during midday trading on Friday, hitting $118.00. The company had a trading volume of 29,224 shares, compared to its average volume of 796,646. Ligand Pharmaceuticals Inc. has a 52 week low of $98.56 and a 52 week high of $278.62. The company has a current ratio of 10.58, a quick ratio of 10.50 and a debt-to-equity ratio of 1.09. The company has a market cap of $2.42 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 0.18 and a beta of 1.37.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Thursday, February 7th. The biotechnology company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.48. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The firm had revenue of $59.59 million during the quarter, compared to the consensus estimate of $52.58 million. During the same period in the previous year, the firm posted $1.31 earnings per share. The business’s revenue was up 18.1% compared to the same quarter last year. On average, research analysts forecast that Ligand Pharmaceuticals Inc. will post 32.16 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Ligand Pharmaceuticals by 2.5% during the third quarter. BlackRock Inc. now owns 3,346,406 shares of the biotechnology company’s stock worth $918,554,000 after acquiring an additional 81,432 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Ligand Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,090,137 shares of the biotechnology company’s stock worth $573,721,000 after purchasing an additional 66,789 shares during the last quarter. Vanguard Group Inc boosted its holdings in Ligand Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc now owns 2,090,137 shares of the biotechnology company’s stock worth $573,721,000 after purchasing an additional 66,789 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Ligand Pharmaceuticals by 44.1% during the third quarter. Renaissance Technologies LLC now owns 754,219 shares of the biotechnology company’s stock worth $207,026,000 after purchasing an additional 230,725 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Ligand Pharmaceuticals by 468.8% during the fourth quarter. Millennium Management LLC now owns 546,957 shares of the biotechnology company’s stock worth $74,222,000 after purchasing an additional 450,791 shares during the last quarter.

LGND has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 15th. HC Wainwright set a $281.00 target price on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a report on Monday, November 19th. ValuEngine raised shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. TheStreet downgraded shares of Ligand Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Wednesday, January 2nd. Finally, Argus reaffirmed a “buy” rating and issued a $150.00 price target (down from $200.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, February 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $210.57.

WARNING: “Jason Aryeh Buys 202 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock” was first posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.wkrb13.com/2019/03/15/jason-aryeh-buys-202-shares-of-ligand-pharmaceuticals-inc-lgnd-stock.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Recommended Story: Understanding each part of a balance sheet

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.